Clinical Trial Update: Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL [Phase 2]

View source ↗

Summary

A Phase 2 trial assesses the efficacy and safety of combining olverembatinib with inotuzumab ozogamicin as a first-line consolidation therapy followed by HSCT i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Inotuzumab ozogamicin (inotuzumab ozogamicin)
• Olverembatinib (Olverembatinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: HSCT, Ph+ ALL | Phase 2 | Status: NOT_YET_RECRUITING